The Australian Pesticides and Veterinary Medicines Authority (APVMA) has published its proposed decision for the reconsideration of neomycin, an antibiotic contained in certain veterinary products for use in both companion and food-producing animals.
Neomycin was nominated for reconsideration due of concerns that the use of oral, intramammary and injectable preparations of neomycin, in accordance with the registered use pattern, could exceed the Australian maximum residue limits (MRLs). The proposed decision includes reconsideration of 9 neomycin products which are either oral, intramammary or injectable preparations and their associated labels.
The APVMA is proposing to:
- cancel 4 chemical product registrations and associated label approvals where no current uses can be supported
- vary and affirm 5 chemical product registrations and associated label approvals where at least one current use can be supported.
A summary of the underlying risk assessments and the product-specific assessment outcomes has been published in the Review Technical Report.
Public consultation on the proposed decision is open for 3 months and will close 26 May 2024. The APVMA Special Gazette, 27 February 2024 includes more information about the proposed decision and how to make a submission.
The APVMA will consider all submissions received during public consultation before making our final regulatory decision.
Enquiries about the proposed decision or the public consultation can be directed to enquiries@apvma.gov.au.
Media enquiries must be directed to media@apvma.gov.au.